Table 2.
Common laboratory characteristics and their relavance with CA19–9 in patients with malignant and benign lesions
| Laboratory characteristics | Malignant | Benign | P value | rs† | P value† |
|---|---|---|---|---|---|
| CA19–9, U/mL | 474.4 (151.8–1325.5) | 267.7 (141.9–639.9) | 0.176 | – | – |
| Total bilirubin, μmol/L | 207.1 (107.1–340.3) | 147.4 (111.3–219.9) | 0.148 | 0.146 | 0.109 |
| Alanine aminotransferase, U/L | 120.5 (51.8–269.8) | 135.0 (16.0–198.0) | 0.49 | 0.068 | 0.456 |
| Aspartate aminotransferase, U/L | 543.0 (317.0–959.0) | 500.5 (260.8–915.3) | 0.805 | 0.086 | 0.399 |
| Gamma-glutamyl transpeptidase, U/L | 441.0 (284.0–682.3) | 418.5 (234.8–603.8) | 0.615 | 0.098 | 0.342 |
| Alkaline phosphatase, U/L | 128.0 (65.0–188.0) | 103.0 (58.3–165.8) | 0.444 | 0.066 | 0.519 |
| Red blood cell count, × 1012 | 3.9 (3.4–4.3) | 4.2 (3.6–4.6) | 0.044 | −0.075 | 0.416 |
| White blood cell count, ×109 | 6.4 (5.1–7.9) | 5.2 (4.1–8.0) | 0.278 | 0.215 | 0.018 |
| Neutrophil percentage, % | 73.5 (64.5–80.4) | 61.5 (55.9–74.6) | 0.016 | 0.26 | 0.004 |
†: Relavance with CA19–9 in malignant patients